|
Design Therapeutics Inc (DSGN) |
|
Design Therapeutics Inc
DSGN's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Design Therapeutics Inc 's sales fell
in III. Quarter 2024 from the same quarter a year ago.
Major Pharmaceutical Preparations industry recorded
growth of revenues by 9.72 %
Design Therapeutics Inc net loss decreased from $-16 millions, to $-13 millions in III. Quarter 2024,
• More on DSGN's Growth
|
|
Design Therapeutics Inc realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 145.94 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.28.
• More on DSGN's Valuation
|
|
|
|
|
Design Therapeutics Inc realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 145.94 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.28.
Design Therapeutics Inc Price to Book Ratio is at 1.38 lower than Industry Avg. of 81.09. and higher than S&P 500 Avg. of 0.01
• More on DSGN's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2024 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com